Local Study of Akatinol Memantine in VaD in Russia

Inclusion Criteria: * Written informed consent obtained from the patient or his/her legal representative if the patient is declared incapable by a court decision. * Understanding of study procedures and willingness to abide to all procedures during the course of the study by the patient or his/her legal representative. * Male and female patients from 50 to 85 years of age (inclusive) suffering from moderate and moderately severe vascular dementia. * Mini-Mental State Examination (MMSE) Test total scores of 10 to 20. * Hachinski's Ischemic Score (HIS) of 7 or higher point. * Availability in the anamnesis of instrumental confirmation of the diagnosis (data methods of neurovisualization - CT or MRT). * For females: menopause or inability to conceive due to other reasons (hysterectomy, etc.). * Availability of a relative or legal representative who lives with the patient, monitors him/her and cares for the patient. Exclusion Criteria: * Alzheimer's disease or secondary types of dementia. * Epilepsy, seizures, schizophrenia, other psychoses, bipolar disorder, alcoholism, drug abuse (including the history thereof). * Other clinically significant neurological or psychiatric disorders. * Severe depression (Hamilton score, HAM-D \> 18 points). * Severe, unstable or decompensated physical disease (including clinically significant laboratory abnormalities) potentially affecting the trial findings. * Contraindications to oral drug intake during the time period determined by the study protocol. * Known hypersensitivity to the investigational product or any of its ingredients. * Administration of nootropic, anti-dementia and typical antipsychotic drugs, tricyclic antidepressants, long-acting benzodiazepines, NMDA receptor antagonists (amantadine, ketamine, dextromethorphan) for 1 month before the enrollment and during the study. * For females: pregnancy and breastfeeding. * Evidence or suspicion that the patient might not comply with the study directive. * Any reason or contraindication which in the investigator's opinion precludes participation in the study. * Patient is direct relative of an employee of the study site or Merz Pharma LLC. * Previous participation in this clinical study. * Participation in another clinical trial within the last 12 weeks prior to screening or ongoing participation in a study.